22.26 USD
↗ 0.80 (3.73%)AT CLOSE (11:59 AM EDT)
Zenas BioPharma, Inc. Common Stock
ZBIONASDAQ • USD
22.25
↗ 0.10 (0.45%)
POST MARKET (AS OF 05:08 PM EDT)
Post Market
AS OF 05:08 PM EDT
22.25
↗ 0.10 (0.45%)
Market: OPEN
Open?$21.53
High?$22.71
Low?$21.46
Prev. Close?$21.46
Volume?642.9K
Avg. Volume?896.6K
VWAP?$22.18
Rel. Volume?0.72x
Bid / Ask
Bid?$21.00 × 400
Ask?$22.26 × 100
Spread?$1.26
Midpoint?$21.63
Valuation & Ratios
Market Cap?1.3B
Shares Out?57.4M
Float?14.3M
Float %?26.6%
P/E Ratio?N/A
P/B Ratio?5.53
EPS?-$6.06
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?5.61Strong
Quick Ratio?5.61Strong
Cash Ratio?1.77Strong
Debt/Equity?0.32Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?5.53FAIR▾
P/S?133.83HIGH▾
P/FCF?N/A▾
EV/EBITDA?-3.4CHEAP▾
EV/Sales?130.63HIGH▾
Returns & Efficiency
ROE?-156.0%WEAK▾
ROA?-98.5%WEAK▾
Cash Flow & Enterprise
FCF?$-172351000
Enterprise Value?$1.3B
Related Companies
Loading...
News
Profile
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Employees
167
Market Cap
1.3B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2024-09-13
Address
852 WINTER STREET, SUITE 250
WALTHAM, MA 02451
Phone: 857-271-2954
WALTHAM, MA 02451
Phone: 857-271-2954